Pires de Camargo Veridiana, van de Rijn Matt, Maestro Roberta, de Alava Enrique, Madoz-Gúrpide Juan, Pilotti Silvana, von Mehren Margaret, Pedeutour Florence, Maki Robert G, Rutkowski Piotr, Thomas David M
Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Semin Oncol. 2009 Aug;36(4):358-71. doi: 10.1053/j.seminoncol.2009.06.008.
Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations that are still estimable targets for new systemic therapeutics, be it pathways involved in angiogenesis or apoptosis. In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma.
尽管存在复杂的遗传学因素，但去分化脂肪肉瘤等非整倍体肿瘤具有特定且可重复的染色体变化，如HDM2和CDK4的扩增，这些变化代表了全身治疗的潜在靶点。此外，存在一些癌细胞存活途径，它们可能不是染色体易位或突变的靶点，但仍是新型全身治疗药物的可评估靶点，无论是参与血管生成还是凋亡的途径。在本综述中，我们研究了特定肉瘤亚型的靶点选择，并通过几个例子展示了用于为肉瘤患者描绘新型治疗途径的新技术。
